Durability of mepolizumab treatment response between doses
I. Pavord (Oxford, United Kingdom), P. Howarth (Brentford, United Kingdom), D. Bratton (Stockley Park, United Kingdom), F. Albers (Research Triangle Park, United States of America), S. Yancey (Research Triangle Park, United States of America)
Source: International Congress 2019 – Clinical studies of asthma treatments
Session: Clinical studies of asthma treatments
Session type: Thematic Poster
Number: 2548
Disease area: Airway diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Pavord (Oxford, United Kingdom), P. Howarth (Brentford, United Kingdom), D. Bratton (Stockley Park, United Kingdom), F. Albers (Research Triangle Park, United States of America), S. Yancey (Research Triangle Park, United States of America). Durability of mepolizumab treatment response between doses. 2548
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you: